hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine

Steffen Falgreen(Chr. Hansen (Denmark)), Martin Bøgsted(Chr. Hansen (Denmark)), Ken H. Young(Duke Medical Center), Jonas Have(Aalborg University Hospital), Lasse Hjort Jakobsen(Aalborg University Hospital), Tarec Christoffer El‐Galaly(Aalborg University Hospital), Kasper Lindblad Nielsen(Aalborg University Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Hans Erik Johnsen(Herlev Hospital), Julie Støve Bødker(Chr. Hansen (Denmark)), Rasmus Froberg Brøndum(Aarhus University), Anders Ellern Bilgrau(Chr. Hansen (Denmark)), Karen Dybkær(Aalborg University Hospital)

PLoS ONE

October 4, 2016

10.1371/journal.pone.0163711

Cited by 10

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

|Journal of Clinical Oncology|2012|682

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

|Blood|2017|429

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma

|Journal of Clinical Oncology|2015|418

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396